Acute Porphyria Drug Database

Monograph

C09CA02 - Eprosartan
Not porphyrinogenic
NP

Rationale
Poorly absorbed, not metabolised.
Chemical description
Angiotensin II receptor antagonist. Weak inhibitor of CYP 2C9 in vitro. Biovailability only 13 % dependent on poor absorbtion. Excreted in unchanged form.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Explore alternative drugs in similar therapeutic classes C09C / C09CA or go back.
Tradenames
This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.


Teveten Teveten Eprosartan · Futuran · Navixen · Regulaten · Tevetens Tevetenz Eprosartan · Teveten Teveten Teveten Teveten Teveten
 
© NAPOS 2025
An unhandled error has occurred. Reload 🗙